Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma

Next Previous
Trial Profile

COTESARC - A multicentre Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Atezolizumab (Primary) ; Cobimetinib (Primary)
  • Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Myxoid liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Sarcoma; Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COTESARC

Most Recent Events

  • 15 Jul 2024 Status changed from recruiting to active, no longer recruiting.
  • 28 Mar 2023 Planned number of patients changed from 120 to 320.
  • 09 Feb 2023 Planned End Date changed from 1 Feb 2025 to 1 Feb 2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top